HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Argyriou, A. A. Articles by Kalofonos, H. P. Search for Related Content PubMed PubMed Citation Articles by Argyriou, A. A. Articles by Kalofonos, H. P. Related Collections Nutritional Peripheral neuropathy All Clinical trials Clinical trials Randomized controlled (CONSORT agreement) All Oncology Chemotherapy-tumor Related Article

Vitamin E for prophylaxis against chemotherapy-induced neuropathy

A randomized controlled trial

From the Neurology Department (Drs. Argyriou, Chroni, Ellul, Papapetropoulos, and Katsoulas) and the Department of Medicine–Division of Oncology (Drs. Koutras, Iconomou, and Kalofonos), University of Patras, Medical School, Rion, Greece.

Address correspondence and reprint requests to Dr. Andreas A. Argyriou, Neurology Department, University of Patras, Medical School, PO Box 1045, Rion, Patras, Greece; e-mail: andargyriou{at}yahoo.gr

Background: The authors conducted a pilot, randomized, open label with blind assessment, controlled trial to determine whether vitamin E supplementation has a neuroprotective effect in chemotherapy-induced peripheral nerve damage.

Methods: Thirty-one patients with cancer treated with six courses of cumulative cisplatin, paclitaxel, or their combination regimens were randomly assigned in two groups and followed by neurologic examination and electrophysiologic study. Patients assigned in Group I (n = 16) received oral vitamin E at a daily dose of 600 mg/day during chemotherapy and 3 months after its cessation were compared to patients of Group II (n = 15), who received no supplementation and served as controls. The severity of neurotoxicity was summarized by means of a modified peripheral neuropathy score.

Results: The incidence of neurotoxicity differed between the two groups, occurring in 4/16 (25%) patients assigned in the vitamin E supplementation group and in 11/15 (73.3%) patients assigned in the control group (p = 0.019). Mean peripheral neuropathy scores were 3.4 ± 6.3 for patients of Group I and 11.5 ± 10.6 for patients of Group II (p = 0.026). The relative risk (RR) of developing neurotoxicity was significantly higher in case of control patients, RR = 0.34, 95% CI = 0.14 to 0.84.

Conclusion: Vitamin E supplementation in cancer patients may have an important neuroprotective effect.

Received May 5, 2004. Accepted in final form August 20, 2004.

See Commentary, page 1

Related Article

January 11 Highlight and Commentary
Neurology 2005 64: 1. [Full Text] [PDF]

This article has been cited by other articles:

				J. J. Lee and S. M. Swain Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents J. Clin. Oncol., April 1, 2006; 24(10): 1633 - 1642. [Abstract] [Full Text] [PDF]

				R. W. Moss Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther, March 1, 2006; 5(1): 63 - 82. [Abstract] [PDF]

				Other articles noted Evid. Based Med., October 1, 2005; 10(5): 157 - 158. [Full Text] [PDF]

				A. Pace, L. Bove, B. Jandolo, A.A. Argyriou, E. Chroni, A. Koutras, J. Ellul, S. Papapetropoulos, G. Katsoulas, G. Iconomou, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial Neurology, August 9, 2005; 65(3): 501 - 502. [Full Text] [PDF]

Correspondence: